Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AcSé CRIZOTINIB : Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug.

NCT02034981 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT02034981
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02034981 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AcSé CRIZOTINIB : Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug.
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2013
Completion date
December 6, 2023
Enrollment
246 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic cancers, metastatic cancer, solid tumors